The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

The following is a summary of “Reducing time delays and enhancing reperfusion eligibility related to stroke suspicion by the ...

Increase the proportion of ischemic stroke patients that receive alteplase or EVT by 5% Reduce the time to treatment for both alteplase and EVT Reduce the door-to-needle time for alteplase treatment ...

On February 27, 2025, the Emergency Department team at Mercer Health was recognized by the Ohio State University Wexner ...

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

As stroke remains one of the leading causes of long-term disability and death worldwide, finding a more efficient and effective treatment is critical for improving patient outcomes and reducing ...

In the United States alone, more than 795,000 people experience a stroke each year, which is about one in every 40 seconds, ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...